8-K: Applied DNA Sciences Reports Q1 Fiscal 2025 Results, Announces Exit from DNA Tagging Business

Applied DNA Sciences reports a 34% increase in total revenues for Q1 2025, alongside strategic restructuring including exiting the DNA Tagging business and a 20% workforce reduction.

Summary

• Applied DNA Sciences announced its Q1 fiscal year 2025 results, showing a 34% increase in total revenues to $1.2 million compared to $891,000 in Q1 2024.
• The company reported an operating loss of $3.0 million, an improvement from the $3.8 million loss in the same period last year.
• Net loss was $2.7 million, compared to a net loss of $1.1 million for the first quarter of fiscal 2024.
• Adjusted EBITDA improved to negative $2.9 million from negative $3.2 million year-over-year.
• The company exited its DNA Tagging and Security Products and Services business segment and implemented a 20% workforce reduction, expected to reduce annual payroll costs by approximately 13%, offset by $300,000 in one-time separation costs.
• The GMP Site 1 facility is complete and certified for commercial operation, with an initial projected manufacturing capacity of approximately ten grams per annum, potentially supporting annual revenues in the range of $10 million to $30 million.
• The company anticipates receiving a first GMP order for IVT templates in the quarter ending June 30, 2025.
• Cash and cash equivalents as of December 31, 2024, were $9.3 million, including $5.7 million from a registered direct offering.

Sentiment

Score: 5

Explanation: The company shows revenue growth and strategic restructuring, but also reports a significant net loss and workforce reduction. The future outlook is promising but uncertain.

Positives

• Total revenues increased by 34% year-over-year.
• Operating loss decreased compared to the same quarter last year.
• Adjusted EBITDA improved year-over-year.
• Completion and certification of the GMP Site 1 facility opens new revenue opportunities.
• Linea DNA platform secured its first-in-human clinical validation.
• Expansion of TR8 PGx testing service to all 50 U.S. states.

Negatives

• The company experienced a net loss of $2.7 million for the quarter.
• The company exited its DNA Tagging and Security Products and Services business segment.
• The company implemented a 20% workforce reduction.

Risks

• The company has a history of net losses and limited financial resources.
• Future demand for biotherapeutics products and services is unknown.
• The amount of revenues and profits that will result from the Linea IVT and/or Linea DNA platforms is unknown.
• There has never been clinical trial material and/or commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms.
• The amount of revenues and profits that will result from its TR8 PGx testing service is unknown.

Future Outlook

The company is focused on commercializing the DNA production capacity of its recently certified GMP Site 1 facility and anticipates initial orders of clinical-grade materials, which they believe will validate the economics of their low-CAPEX approach to enzymatic DNA production.

Management Comments

• Our first quarter performance reflects the implementation of a strategic restructuring to support our growth through our synthetic DNA manufacturing strategy, stated Dr. James A. Hayward, Chairman and CEO of Applied DNA.
• We are taking difficult but necessary steps to optimize our corporate structure to lower our cash burn rate and stabilize our financial position to ensure our ability to execute against near-term operational goals.
• As we move through fiscal 2025, we are focused on commercializing the DNA production capacity of our recently certified GMP Site 1 facility, concluded Dr. Hayward.
• We are preparing for initial orders of clinical grade materials, the acquisition of which we believe will validate the economics of our proprietary low-CAPEX approach to enzymatic DNA production in front of an industry that is actively seeking cell-free, synthetic alternatives to traditional pDNA production processes.
• We believe our capacity for the GMP production of DNA in an economical, fast, and scalable manner to advance the rapid development of genetic medicines is a unique competitive advantage in the marketplace and is the lynchpin to our future success.

Industry Context

Applied DNA Sciences' focus on synthetic DNA manufacturing and mRNA therapeutics aligns with the growing demand for cell-free alternatives to traditional plasmid DNA production in the genetic medicine industry. The completion of their GMP Site 1 facility positions them to capitalize on this trend.

Comparison to Industry Standards

• The projected manufacturing capacity of Site 1, approximately ten grams per annum, which supports potential annual revenues in the range of $10 million to $30 million, is competative with other companies in the space.
• The company's Linea DNA platform secured its first-in-human clinical validation with Linea DNA used as a critical component in the manufacture of a CAR-T therapy, which is a significant milestone in the competitive CAR-T therapy space.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the revenue growth and strategic restructuring.
• Employees have been impacted by the 20% workforce reduction.
• Customers of the DNA Tagging business will be affected by the exit from that segment.
• The company's focus on synthetic DNA manufacturing and mRNA therapeutics could benefit patients and the broader healthcare industry.

Next Steps

• Commercialize the DNA production capacity of the recently certified GMP Site 1 facility.
• Secure initial orders of clinical-grade materials.
• Continue process development with a U.S.-based therapeutics developer.
• Expand the TR8 PGx testing service to all 50 U.S. states.

Key Dates